Showing 1621-1630 of 20878 results for "".
- Revolutionizing Vaccine Strategies: Insights from Gut Mucosal Immunityhttps://reachmd.com/news/revolutionizing-vaccine-strategies-insights-from-gut-mucosal-immunity/2484504/A University of Toronto study found that gut immune cells can use an atypic
- New Insights into Uterine Contraction Mechanics: Implications for Labor Managementhttps://reachmd.com/news/new-insights-into-uterine-contraction-mechanics-implications-for-labor-management/2484492/A recent preclinical study suggests that stretch- and pressure-sensitive molecular sensors influence the timing and strength of uterine contractions.
- APPLAUSE-IgAN: Landmark Phase III Results for Iptacopanhttps://reachmd.com/news/applause-igan-landmark-phase-iii-results-for-iptacopan/2484489/Novartis reported that the Phase III APPLAUSE-Ig
- Monoclonal Antibodies in RSV Prevention: Potential Game-Changer for Infant Healthhttps://reachmd.com/news/monoclonal-antibodies-in-rsv-prevention-potential-game-changer-for-infant-health/2484475/A recent study found that nirsevimab reduced RSV-related hospitalizations by 79% overall, substantially lowering severe infant outcomes during the winter
- The Impact of Climate Change on Infectious Disease Spread: Challenges and Responseshttps://reachmd.com/news/the-impact-of-climate-change-on-infectious-disease-spread-challenges-and-responses/2484476/The COP30 report finds climate change is expanding geographic risk for vectorborne and zoonotic infections,
- Assessing the Impact of Ablation Plus Immunotherapy in Advanced NSCLC: Insights from the BOOSTER Phase 2 Trialhttps://reachmd.com/news/assessing-the-impact-of-ablation-plus-immunotherapy-in-advanced-nsclc-insights-from-the-booster-phase-2-trial/2484459/In the BOOSTER trial, adding local tumor ablation to ongoing anti-PD-1/L1 therapy markedly extended progression-free survival in advanced NSCLC with oligo-residual disease. The randomized phase 2 trial demonstrates an immediately actionable approach to prolong diseas
- Optimal Exercise Therapy for Chronic Ankle Instability: Insights from a Systematic Review and Meta-Analysishttps://reachmd.com/news/optimal-exercise-therapy-for-chronic-ankle-instability-insights-from-a-systematic-review-and-meta-analysis/2484477/A recent systematic review and meta-analysis of randomized trials shows exercise therapy improves patient-oriented function in chronic ankle instability (CAI), making targete
- EBV's Role in Lupus Pathogenesis: Insights from Stanford Researchhttps://reachmd.com/news/ebvs-role-in-lupus-pathogenesis-insights-from-stanford-research/2484465/A Stanford-led study demonstrates that Epstein-Barr virus (EBV) infection reprograms B cells into a defined driver phenoty
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://reachmd.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum
- Physiology-Guided Revascularization Strategies in Older Myocardial Infarction Patients: Clinical Insightshttps://reachmd.com/news/physiology-guided-revascularization-strategies-in-older-myocardial-infarction-patients-clinical-insights/2484469/A recent trial found that physiology-guided complete revascularization reduces major events at three years in older MI patients, shifting how clinicians weigh revascularization strategies. The trial reframes practice for older adults with myocardial infarction (MI) a